Alset 3Q 2026: Revenue $938.94K, EPS $0.13 — 10-Q Summary

Alset reported 3Q 2026 revenue of $938.94K, down 6% YoY, but net income rose 242% to $5.17M, supported by a $6.1M gain on ESYN deconsolidation. EPS increased to $0.13. Real estate rental revenue grew 3%, while other revenue declined 27%.

Original reporting
Published Nov 13, 2026, 10:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Alset 3Q 2026: Revenue $938.94K, EPS $0.13 — 10-Q Summary — source image
Decision brief

The 30-second read

$AEINeutralLow
01

Why it matters

The earnings release provides fresh data for traders evaluating micro‑cap opportunities, with a notable net income jump offset by lower revenue.

02

Market read

The report is a primary disclosure for Alset, offering modest trading ideas for short‑term investors.

03

What to watch

The $6.1M gain from ESYN deconsolidation is a one‑time item that may not repeat, and the decline in other‑business revenue signals underlying weakness.

Relevance 6/10Novelty 6/10Timing: post-market today

Background

Alset Inc. filed a Form 10‑Q for Q3 2026, showing mixed performance across its business lines.

Company-level read

Ticker impact

$AEINeutralMedium confidence
Context

Alset Inc. reported Q3 2026 results with revenue $938.94K, a 6% YoY decline and net income $5.17M, a 242% increase.

Expected impact

modest upside as the earnings beat net income expectations despite revenue decline

Evidence & confidence

The surprise gain in net income and deconsolidation gain may attract short‑term buying, but the revenue drop limits upside.

Market effects

Limited impact on the broader real estate and F&B sectors; highlights volatility in Alset's diversified revenue streams.

Primarily affects US micro‑cap investors; no broader regional effect.

Minimal global relevance due to the company's small size and niche operations.

Counterpoint

Investors may view the revenue decline as a red flag and short the stock despite the net income surge.

Key entities

  • Alset Inc.

    Micro‑cap real estate and F&B operator reporting Q3 2026 results.

Related articles

$FTAIMed

FTAI, AEI Team Up To Supply, Support 737-800Fs

FTAI Aviation and AEI said they will partner to convert Boeing 737-800s into freighters. FTAI will source midlife aircraft, buy AEI conversion kits, and supply CFM56-7 engines; AEI will convert them via its network. Freighters will be sold or placed into FTAI’s SPVs for leasing with long-term engine support. First conversion starts soon at Staeco in China.

$ZTEKFMed

Zentek Ltd. (ZTEKF): Financial results for FY2027

Zentek Ltd. (ZTEKF) furnished an SEC Form 6-K — earnings release. Zentek Q2 Fiscal 2027 Results News Release Zentek Strengthens Its Balance Sheet, Ends Second Quarter with $13.6 Million in Cash Working capital of $11.3 million at September 30, 2026, compared with a deficit of $1.3 million at March 31, 2026 Guelph, Ontario, November 16, 2026. Ze

$WBMedAI 8/10

Alibaba Is Pulling Back From This 10% Dividend Stock

Weibo (WB) missed Q3 revenue and earnings expectations, with advertising revenue from Alibaba (BABA) falling 33%. Shares dropped 4% premarket. GAAP net income fell 88.91%, operating cash flow turned negative, and long-term loans were reclassified as current. The dividend yield is 10.6%, but earnings are declining. CEO Gaofei Wang highlighted AI efforts, but ad budgets remain a concern.

$SLSHighAI 9/10

SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint

SELLAS Life Sciences (SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, Galinpepimut-S (GPS), meeting the primary endpoint of overall survival. GPS reduced the risk of death by 41% compared to standard treatment, with median OS of 24.0 months vs. 14.7 months. The company plans to discuss an accelerated FDA filing pathway and aims for a BLA submission in early 2027. Shares surged over 255% in premarket trading.